Managing POTS: what do the guidelines say?

An overview of the approaches described in guidelines, with no individual advice or doses: choices are made together with a health professional.

10 sources
5 min read
Clinical review
Verified 8 November 2026

Key points

Guidelines place non-drug measures first; multidisciplinary care may be considered (a low-level recommendation in the HRS consensus), and care is individualized according to symptoms, coexisting conditions and contraindications. ^{[1, 2, 3]}
The non-drug approaches cited include identifying medicines that may worsen symptoms, managing fluid and salt intake where appropriate, compression garments and adapted activity programs. These are not universal instructions: they are chosen together with a health professional. ^{[1, 2, 4]}
Medicines from several classes are used in some situations, but the level of evidence and the indications differ. The 2026 systematic review included only 45 studies out of 3,853 references initially identified and concludes that large randomized trials are still needed. ^[4]
The HRS consensus does not recommend repeated saline infusions as routine care, for lack of evidence; repeated intravenous access carries risks. It does, however, consider a one-off infusion reasonable during acute decompensation. ^[1]
For people with ME/CFS, the NG206 guideline from NICE (the UK’s National Institute for Health and Care Excellence) advises against exercise programs that use fixed, incremental increases in activity. This recommendation concerns diagnosed ME/CFS; it is neither a POTS guideline nor a recommendation that applies automatically to post-exertional malaise on its own. ^[5]

General principles

Non-drug measures mentioned in guidelines

What is established

Consensus documents describe several categories of measures:

identifying, and where necessary reviewing with the prescriber, medicines that may worsen symptoms;
discussing fluid and sodium intake when the medical context allows;
considering compression garments to limit venous pooling (blood collecting in the leg veins when standing);
adapting posture and some daily activities to limit triggers;
where suitable, building an individualized, progressive physical activity program, often starting with forms that reduce orthostatic stress.

These principles appear in the HRS consensus, the Canadian position statement and clinical reviews. They are not individual prescriptions and may be unsuitable in the presence of certain heart, kidney or vascular diseases or other contraindications. ^{[1, 2, 3, 8]}

Drug approaches: a non-prescriptive overview

Safety points and interventions not recommended as routine care

Taking ME/CFS and post-exertional malaise into account

Guidance by country

What is established

United States / international: the 2015 HRS consensus describes non-drug measures and drug options with classes and levels of evidence. The articles from the 2019 NIH consensus meeting, published in 2021, highlight the lack of robust treatment data and the need for collaborative trials. ^{[1, 6]}
Canada: the 2020 Canadian Cardiovascular Society position statement provides a diagnostic and treatment synthesis developed using the GRADE method. ^[2]
France: the 2024 long COVID guide from the French National Authority for Health (HAS) mentions non-drug measures for dysautonomic symptoms and refers to specialist cardiology care for specific treatments. This document is limited to the post-COVID care pathway and does not replace a full guideline covering all forms of POTS. ^[8]
United Kingdom: no NICE guideline dedicated to POTS was identified in this search. NICE NG206 is relevant when ME/CFS is also present; NICE NG188 covers the long-term effects of COVID-19 in general. The NHS page on PoTS is a public information resource, not a NICE recommendation. ^{[5, 9, 10]}

Overall level of evidence

References and level of evidence

Sheldon RS, Grubb BP II, Olshansky B, et al. 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. Heart Rhythm, 12(6), e41–e63 2015. DOI: 10.1016/j.hrthm.2015.03.029. PMID: 25980576.(guideline or consensus)
Limitations: 2015 recommendations; several areas rest on a low level of evidence. Population: international consensus of cardiovascular and autonomic societies. Read: full text (HRS PDF).
Declared conflicts of interest: Industry ties declared by several authors (appendix 1: Medtronic, Boston Scientific, St. Jude, Lundbeck, Biotronik…); NHLBI funding
Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance. Canadian Journal of Cardiology, 36(3), 357–372 2020. DOI: 10.1016/j.cjca.2019.12.024. PMID: 32145864.(guideline or consensus)
Limitations: Synthesis and recommendations; some interventions rest on limited evidence. Population: Canadian position statement covering diagnosis and management. Read: abstract only.
Declared conflicts of interest: Not reviewed in the part of the source that was read
Raj SR, Fedorowski A, Sheldon RS. Diagnosis and management of postural orthostatic tachycardia syndrome. CMAJ, 194(10), E378–E385 2022. DOI: 10.1503/cmaj.211373. PMID: 35288409.(evidence synthesis)
Limitations: Narrative synthesis, not a formal national guideline; differences in protocols. Population: clinical review and practical recommendations. Read: full text (cmaj.ca).
Declared conflicts of interest: All three authors declare research funding, fees or consulting activities; Raj and Sheldon also declare expert witness work or patents
Schiweck N, Langer K, Maier A, Vilser D, Spiegler J. Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS). Clinical Autonomic Research, 36(1), 3–16 2026. DOI: 10.1007/s10286-025-01172-2. PMID: 41225175.(evidence synthesis)
Limitations: Heterogeneous treatments and a lack of large randomized trials. Population: systematic review; 45 studies included out of 3,853 references. Read: abstract.
Declared conflicts of interest: Not visible in the abstract consulted
NICE. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206). NICE guideline 2021.(guideline or consensus)
Limitations: Not a POTS guideline; relevant only to ME/CFS and the associated post-exertional malaise. Population: children, young people and adults with suspected or diagnosed ME/CFS. Read: online recommendations (nice.org.uk), published October 29, 2021.
Declared conflicts of interest: Institutional document; committee declarations according to NICE
Raj SR, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome (POTS): Priorities for POTS care and research from a 2019 National Institutes of Health Expert Consensus Meeting - Part 2. Autonomic Neuroscience, 235, 102836 2021. DOI: 10.1016/j.autneu.2021.102836. PMID: 34246578.(guideline or consensus)
Limitations: Not a cohort study; several measurement and research needs remain unresolved. Population: expert consensus and review of knowledge gaps. Read: abstract.
Declared conflicts of interest: Not reviewed in the part of the source that was read
Sivakoti K, Cortez MM, Fedorowski A, Fudim M, Lau DH, Novak P, Rowe PC, Schofield JR, Blitshteyn S, International POTS and Dysautonomia Expert Panel. Postural orthostatic tachycardia syndrome (POTS) and dysautonomia: International multidisciplinary expert consensus. The American Journal of Medicine, published online August 28, 2026 2026. DOI: 10.1016/j.amjmed.2026.08.012. PMID: 42665152.(guideline or consensus)
Limitations: Expert consensus, not a controlled trial or a formal systematic review; full text not consulted. Population: international Delphi consensus; 31 statements, 40 contributors from 7 countries, adults and pediatrics. Read: abstract.
Declared conflicts of interest: Not visible in the abstract consulted
Haute Autorité de santé. Parcours de soins de l'adulte avec des symptômes prolongés de la Covid-19. HAS, care pathway guide, approved April 11, 2024 2024.(guideline or consensus)
Limitations: Does not cover POTS outside the post-COVID setting; post-COVID care pathway guide. Population: adults and adolescents aged 15 or older with prolonged symptoms after COVID-19. Read: full text.
Declared conflicts of interest: The group's public declarations of interest were analyzed by HAS and judged compatible
NICE, SIGN, RCGP. COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188). NICE 2020.(guideline or consensus)
Limitations: General guideline on long COVID; not a standalone guideline on the diagnosis or treatment of POTS. Population: adults and children with prolonged symptoms after COVID-19. Read: overview page (updated November 11, 2021).
Declared conflicts of interest: Not reviewed in the part of the source that was read
NHS. Postural tachycardia syndrome (PoTS). NHS Health A to Z 2026.(expert opinion)
Limitations: Public information source, not a clinical practice guideline or a study. Population: information for the UK public. Read: full text of the web page.
Declared conflicts of interest: Not applicable / not displayed on the page consulted

Written by: AI-assisted literature research (ChatGPT) and AI-assisted writing (Claude)
Editor: Jean Viry-Babel
Review status: Clinical review: Dr Françoise Charmoillaux (anesthesiologist)
Approved on: 9 November 2026
Literature search: 8 November 2026
Last verified: 8 November 2026
Geographic scope: international, United States, France, United Kingdom, Canada
Audience: everyone
Conflicts of interest: No known financial ties. Separately, the publisher is developing a personal approach to these conditions under the name Connected Conditions, which is not cited here (see the legal notice).
Limitations of this page: Non-prescriptive overview: no doses and no individual guidance on what to do. Many approaches rest on limited evidence.